Literature DB >> 8392419

The application of EPR dosimetry for radiotherapy and radiation protection.

R Kudynski1, J Kudynska, H A Buckmaster.   

Abstract

This paper reports the first clinical trial of the application of the continuous wave electron paramagnetic resonance (CW-EPR) spectrum of alanine to determine the radiation dose received by a patient. The results of these measurements are compared with those obtained using thermoluminescent dosimetry (TLD) simultaneously. The 9 GHz EPR measurements were made at 13 degrees C. The time stability of the radiation induced radicals in alanine was confirmed. The fractionated radiation doses received in the clinical trial were determined from a calibration curve (linear regression coefficient r = 0.9995) obtained by irradiating L-alanine samples with 60-800 cGy doses using cobalt 60 gamma rays obtained from an Eldorado 8 Cobalt 60 unit at a rate of approximately 60 cGy/min. It is shown that the absorbed dose in tissue-equivalent material can be determined using EPR spectroscopy with an accuracy of approximately 3% at low dose levels (60 cGy) whereas the error using TLD is approximately 5% and that this method of dose determination is preferable to the present TLD method because it is simpler and more accurate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392419     DOI: 10.1016/0969-8043(93)90042-9

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  2 in total

Review 1.  Clinical applications of alanine/electron spin resonance dosimetry.

Authors:  Oswaldo Baffa; Angela Kinoshita
Journal:  Radiat Environ Biophys       Date:  2014-01-08       Impact factor: 1.925

2.  Prospective superficial EPR in-vivo dosimetry study during hypofractionated radiotherapy of breast cancer patients treated with helical tomotherapy.

Authors:  Sebastian Höfel; Matteo Gandalini; Michael K Fix; Malte Drescher; Felix Zwicker
Journal:  Radiat Oncol       Date:  2021-10-30       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.